Clinical value of atezolizumab plus bevacizumab for first-line unresectable hepatocellular carcinoma (HCC): A network meta-analysis.

被引：0
|
作者：
Vogel, Arndt
Rimassa, Lorenza
Sun, Hui-Chuan
Abou-Alfa, Ghassan K.
El-Khoueiry, Anthony B.
Pinato, David James
Daigl, Monica
Alvarez, Javier Sanchez
Orfanos, Panos
Leibfried, Michael
Zumofen, Marie-Helene Blanchet
Gaillard, Vincent
Merle, Philippe
机构：
[1] Hannover Med Sch, Hannover, Germany
[2] Humanitas Univ, Pieve Emanuele, Italy
[3] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China
[4] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[5] Weill Cornell Med Coll, New York, NY USA
[6] USC Norris Comprehens Canc Ctr, Keck Sch Med, Div Med Oncol, Los Angeles, CA USA
[7] Imperial Coll London, Dept Surg & Canc, London, England
[8] F Hoffmann La Roche Ltd, Basel, Switzerland
[9] Genentech Inc, San Francisco, CA 94080 USA
[10] Hop Croix Rousse, Dept Hepatol, Lyon, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4585
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Efficacy of Atezolizumab Plus Bevacizumab Versus Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma: a Meta-analysis
    Mah I Kan Changez
    Maimoona Khan
    Muhammad Uzair
    Muhammad Fawad Tahir
    Maryam Mohsin
    Amna Faiyaz Hussain
    Vania Saqib
    Muhammad Khizer Molani
    Aisha Habib Ahmed
    Saad Khalid
    Journal of Gastrointestinal Cancer, 2024, 55 : 467 - 481
  • [32] Efficacy of Atezolizumab Plus Bevacizumab Versus Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma: a Meta-analysis
    Changez, Mah I. Kan
    Khan, Maimoona
    Uzair, Muhammad
    Tahir, Muhammad Fawad
    Mohsin, Maryam
    Hussain, Amna Faiyaz
    Saqib, Vania
    Molani, Muhammad Khizer
    Ahmed, Aisha Habib
    Khalid, Saad
    JOURNAL OF GASTROINTESTINAL CANCER, 2024, 55 (01) : 467 - 481
  • [33] PRELIMINARY RESULTS OF A COST EFFECTIVENESS MODEL OF ATEZOLIZUMAB PLUS BEVACIZUMAB IN UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC) IN FRANCE
    de Gennes, Dubois C.
    Mazaleyrat, B.
    Alvarez, Sanchez J.
    Cawston, H.
    VALUE IN HEALTH, 2020, 23 : S436 - S436
  • [34] Comparative Efficacy of Atezolizumab plus Bevacizumab and Other Treatment Options for Patients with Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis
    Vogel, Arndt
    Rimassa, Lorenza
    Sun, Hui-Chan
    Abou-Alfa, Ghassan K.
    El-Khoueiry, Anthony
    Pinato, David J.
    Sanchez Alvarez, Javier
    Daigl, Monica
    Orfanos, Panos
    Leibfried, Michael
    Blanchet Zumofen, Marie-Helene
    Gaillard, Vincent E.
    Merle, Philippe
    LIVER CANCER, 2021, 10 (03) : 240 - 248
  • [35] Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients
    Persano, Mara
    Rimini, Margherita
    Tada, Toshifumi
    Suda, Goki
    Shimose, Shigeo
    Kudo, Masatoshi
    Cheon, Jaekyung
    Finkelmeier, Fabian
    Lim, Ho Yeong
    Presa, Jose
    Masi, Gianluca
    Yoo, Changhoon
    Lonardi, Sara
    Tovoli, Francesco
    Kumada, Takashi
    Sakamoto, Naoya
    Iwamoto, Hideki
    Aoki, Tomoko
    Chon, Hong Jae
    Himmelsbach, Vera
    Niizeki, Takashi
    Montes, Margarida
    Vivaldi, Caterina
    Solda, Caterina
    Stefanini, Bernardo
    Hiraoka, Atsushi
    Sho, Takuya
    Nishida, Naoshi
    Steup, Christoph
    Iavarone, Massimo
    Di Costanzo, Giovanni
    Marra, Fabio
    Tamburini, Emiliano
    Cabibbo, Giuseppe
    Foschi, Francesco Giuseppe
    Silletta, Marianna
    Hirooka, Masashi
    Kariyama, Kazuya
    Tani, Joji
    Atsukawa, Masanori
    Takaguchi, Koichi
    Itobayashi, Ei
    Fukunishi, Shinya
    Tsuji, Kunihiko
    Ishikawa, Toru
    Tajiri, Kazuto
    Ochi, Hironori
    Yasuda, Satoshi
    Toyoda, Hidenori
    Ogawa, Chikara
    EUROPEAN JOURNAL OF CANCER, 2023, 189
  • [36] Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in advanced hepatocellular carcinoma
    Persano, M.
    Rimini, M.
    Tada, T.
    Suda, G.
    Shimose, S.
    Kudo, M.
    Cheon, J.
    Finkelmeier, F.
    Presa, J.
    Masi, G.
    Yoo, C.
    Lonardi, S.
    Piscaglia, F.
    Iavarone, M. A.
    Tamburini, E.
    Cabibbo, G.
    Silletta, M.
    Cascinu, S.
    Scartozzi, M.
    Gardini, A. Casadei
    ANNALS OF ONCOLOGY, 2023, 34 : S603 - S604
  • [37] Impact of metformin, statin, aspirin and insulin on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
    Rimini, M.
    Amadeo, E.
    Vitiello, F.
    Foti, S.
    Persano, M.
    Tada, T.
    Suda, G.
    Shimose, S.
    Kudo, M.
    Cheon, J.
    Finkelmeier, F.
    Lim, H. Y.
    Piscaglia, F.
    Masi, G.
    Yoo, C.
    Lonardi, S.
    Rossari, F.
    Camera, S.
    Gardini, A. Casadei
    Presa, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S1548 - S1548
  • [38] The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey
    Akyildiz, Arif
    Guven, Deniz Can
    Ozluk, Ahmet Anil
    Ismayilov, Rashad
    Mutlu, Emel
    Unal, Olcun Umit
    Yildiz, Ibrahim
    Iriagac, Yakup
    Turhal, Serdar
    Akbas, Sinem
    Bayram, Ertugrul
    Telli, Tugba Akin
    Turkoz, Fatma Paksoy
    Ozcelik, Melike
    Erciyestepe, Mert
    Selvi, Oguzhan
    Gulbagci, Burcu
    Erturk, Ismail
    Isleyen, Zehra Sucuoglu
    Kahraman, Seda
    Akdag, Mutianur Ozkorkmaz
    Hamitoglu, Buket
    Unek, Ilkay Tugba
    Unal, Caglar
    Hacibekiroglu, Ilhan
    Arslan, Cagatay
    Azizy, Abdulmunir
    Helvaci, Kaan
    Demirci, Umut
    Dizdar, Omer
    Basaran, Mert
    Goker, Erdem
    Sendur, Mehmet Ali
    Yalcin, Suayib
    MEDICINE, 2023, 102 (45) : E35950
  • [39] Usefulness of atezolizumab plus bevacizumab as second-line therapy for patients with unresectable hepatocellular carcinoma
    Yamaba, Shinpei
    Imai, Yukinori
    Sugawara, Kayoko
    Uchida, Yoshihito
    Fuchigami, Akira
    Uchiya, Hiroshi
    Nakayama, Nobuaki
    Mochida, Satoshi
    PLOS ONE, 2024, 19 (04):
  • [40] First-Line Targeted Therapy for Hepatocellular Carcinoma: Role of Atezolizumab/Bevacizumab Combination
    Tella, Sri Harsha
    Kommalapati, Anuhya
    Mahipal, Amit
    Jin, Zhaohui
    BIOMEDICINES, 2022, 10 (06)
12345